# Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

> **NCT05841381** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 876 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05841381
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-05-06
- **Primary completion:** 2028-05-06
- **Final completion:** 2033-05-06
- **Target enrollment:** 876 (ESTIMATED)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841381, "Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05841381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*